Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Inclusion Criteria: 1\. Patient successfully completed the Phase 1b/2a study with WVE-120102, WVE-HDSNP2-001. Exclusion Criteria: 1. Received an investigational drug other than WVE-120102, including an investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer. 2. Inability to undergo brain MRI (with or without sedation). 3. Clinically significant medical finding on the physical examination other than HD that, in the judgment of the Investigator, will make the patient unsuitable for participation in and/or completion of the study procedures.